Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

[Background]: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–m...

Full description

Bibliographic Details
Authors: Suvannasankha, Attaya, Bahlis, Nizar J., Trudel, Suzanne, Weisel, Katja, Koenecke, Christian, Oriol, Albert, Voorhees, Peter, Alonso, Aranzazu A., Callander, Natalie S., Mateos, Maria Victoria, Reddy, Nishitha, Hakim, Shawn, LaMacchia, John, Patel, Nashita, Williams, Danaé, Jewell, Roxanne C., Zhou, Xiangdong, Gupta, Ira, Opalinska, J., Nooka, Ajay
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/387906
Online Access:http://hdl.handle.net/10261/387906
Access Level:Open access
Keyword:Belantamab mafodotin
Pembrolizumab
Refractory multiple myeloma
Dose‐escalation
Dose‐ expansion
Benefit‐risk profile
Safety
Description
Summary:[Background]: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM.

Similar Items